50 results on '"Amini-Adle, Mona"'
Search Results
2. Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study
3. Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database
4. Reflectance Confocal Microscopy in Dermatology
5. Impact of systematic screening of pheochromocytoma in patients with neurofibromatosis type 1
6. Vesiculobullous skin lesions on the hands and face
7. Individual Response to Radiation of Individuals with Neurofibromatosis Type I: Role of the ATM Protein and Influence of Statins and Bisphosphonates
8. Benefit from adjuvant radiotherapy according to the number of risk factors in cutaneous squamous cell carcinoma
9. Effets secondaires rhumatologiques immuno-induits par les inhibiteurs de points de contrôle de la réponse immunitaire
10. Reflectance Confocal Microscopy in Dermatology
11. Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
12. Traitements actuels en situation métastatique
13. Benefit of skin surgical revision in high-risk basal cell carcinoma according to histopathological margins
14. La NF1 : ce que le dermatologue doit savoir
15. Neurofibromatose en mosaïque
16. Proposition d’algorithme de prise en charge dans la NF1
17. Progrès dans la prise en charge médicamenteuse des NF1
18. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients
19. Combined deep penetrating naevus in a capsular nodal naevus
20. Reflectance Confocal Microscopy in Dermatology
21. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study
22. Supplementary Tables from Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
23. Impact of the Covid‐19 pandemic on melanoma diagnosis: A retrospective study from the French clinical database of melanoma patients (RIC‐Mel).
24. Gastric signet-ring cell adenocarcinoma masquerading as sarcoidosis
25. Vogt-Koyanagi-Harada–like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma
26. Intérêt de la radiothérapie adjuvante selon le nombre de facteurs de risque dans la prise en charge des carcinomes épidermoïdes cutanés
27. Enquête nationale de pratique auprès des dermatologues et radiothérapeutes sur la prise en charge des carcinomes épidermoïdes cutanés par radiothérapie
28. Individual Response to Radiation of Individuals with Neurofibromatosis Type I: Role of the ATM Protein and Influence of Statins and Bisphosphonates
29. Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database.
30. Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
31. Cemiplimab removed from reimbursable drugs in France
32. Vaccination anti-SARS-CoV-2/Covid-19 et inhibiteurs de points de contrôle immunitaire dans le cancer.
33. Zanubrutinib-associated ecchymotic lesions
34. Association of Anti–Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma
35. Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.
36. Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
37. Évaluation de la cryothérapie percutanée en traitement des neurofibromes plexiformes et des neurofibromes non résécables au cours de la NF1
38. Remitting Seronegative Symmetric Synovitis With Pitting Edema Associated With Partial Melanoma Response Under Anti–CTLA‐4 and Anti–Programmed Death 1 Combination Treatment
39. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors
40. Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.
41. Signet Ring-Like Cells: A New Reflectance Confocal Microscopy Clue of Interface Dermatitis Correlated to Basal Cell Vacuolization in Histopathology
42. Scleromyxedema: Successful Treatment with Thalidomide in Two Patients
43. Signet Ring-Like Cells: A New Reflectance Confocal Microscopy Clue of Interface Dermatitis Correlated to Basal Cell Vacuolization in Histopathology.
44. Scleromyxedema: Successful Treatment with Thalidomide in Two Patients.
45. Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM network.
46. Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma.
47. Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.
48. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
49. Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
50. [Rheumatic immune adverse events related to immune checkpoint inhibitors-(IrAEs related to ICI)].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.